[HDL-cholesterol: from risk factor to therapeutic target].
The protective role of HDL-cholesterol against atherosclerosis has been established in epidemiological and experimental studies. In spite of this, there are a few of clinical trials that have unequivocally demonstrated that raising HDL-cholesterol reduces the cardiovascular risk. In the present article we review the putative protective mechanisms associated with HDL particles, the evidence linking HDL-cholesterol increase with a reduction in cardiovascular risk as well as the pharmacological and non-pharmacological therapies for increasing HDL-cholesterol. Finally, we comment on experimental drugs currently under development, that elevate HDL-cholesterol.
Lahoz
Carlos
C
Hospital Carlos III, Madrid, España. clahoz.hciii@salud.madrid.org
Mostaza
José M
JM
D002318:Cardiovascular Diseases / Q000209:etiology* / Q000517:prevention & control*; D008076:Cholesterol, HDL / Q000097:blood* / Q000187:drug effects*; D002995:Clofibric Acid / Q000627:therapeutic use; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications / Q000188:drug therapy; D009525:Niacin / Q000627:therapeutic use; D012307:Risk Factors
D008076:Cholesterol, HDL; D009525:Niacin; D002995:Clofibric Acid